Merger Gamesmanship: Genentech Had Countered First Roche Bid With 26% Higher Asking Price
This article was originally published in The Pink Sheet Daily
Executive Summary
Roche SEC filing outlines several “key areas of disagreement,” including assumptions on annual product price increases and pipeline productivity.
You may also be interested in...
The Genentech Sales Pitch: Higher Values R Us
Despite a blizzard, Genentech attracts more than 300 Wall Street analysts and investors to hear why Roche’s bid undervalues the biotech.
The Genentech Sales Pitch: Higher Values R Us
Despite a blizzard, Genentech attracts more than 300 Wall Street analysts and investors to hear why Roche’s bid undervalues the biotech.
How Sweet It Isn’t: Genentech Investors Want Higher Roche Bid
New survey suggests Genentech’s minority shareholders won’t tender at the $86.50 price.